Simultaneously the strong effect of blocking both PD-L1 and CTLA-4 pathway (durvalumab + tremelimumab) was also observed in unresectable HCC but not in HBV infected subgroup. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.